Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA-638 in persistent asthma
NCT00425061Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Primary completion
- Aug 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of anrukinzumab in asthma (3 arms), sponsored by Pfizer. Primary endpoint: Morning Peak Expiratory Flow Rate at Day 112. Started Feb 2007; status: completed.
02
Drugs
anrukinzumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00425061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425061.